▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Samsung BioLogics likely to turnaround this year

  • PUBLISHED :June 30, 2017 - 14:11
  • UPDATED :June 30, 2017 - 17:05
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Samsung BioLogics is expected to post its first-ever operating profit this fiscal year, according to analysts on June 30.

Samsung Group’s biologic drug manufacturing arm is likely to report operating profit of 30.8 billion won (US$26.93 million) this year, compared with a 30.4 billion won loss in 2016, the Korea Investment & Securities forecast. 



“Although the operating profit is small, it is positive that the company has charted a clear direction for long-term growth,” Kevin Jin, analyst of the brokerage firm said.

He also estimated Samsung BioLogics’ net loss will narrow to 147.5 billion won from 176.8 billion won last year. The losses so far have stemmed largely from the research and development expenses incurred by its subsidiaries Samsung Bioepis and Archigen Biotech. Capacity utilization of the company’s first plant will fall in 2018 due to suspended production from item changes, but this is expected to be offset by rising utilization at the second production line.

“All in all, Samsung BioLogics is likely to get on a full-blown growth track from 2018,” Jin said. 



Currently, the firm boasts a combined capacity of 182,000 liters at its two plants. Once its third plant is completed by end-2018, the capability will bolster to 362,000 liters, the world’s largest biopharma product manufacturing capability.

The firm supplies biological therapies to global drug makers, including Bristol-Myers Squibb, Roche, J&J subsidiary Cilag and Samsung Bioepis.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS